Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease - PubMed (original) (raw)
Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease
Sumihiro Maeda et al. Neurosci Res. 2006 Mar.
Abstract
Development of neurofibrillary tangles (NFTs) is a pathological hallmark in various neurodegenerative disorders including Alzheimer's disease (AD). Recently, we identified a granular tau oligomer having a pre-filamentous structure. To determine the role of this oligomer in NFT formation, we quantified the amount of granular tau oligomer in 21 frontal cortex samples, each displaying varying degrees of Braak-staged NFT pathology. Here we report that granular tau oligomer levels in frontal cortex were significantly increased, even in brains displaying Braak-stage I neuropathology, a stage at which clinical symptoms of AD and NFTs in frontal cortex are believed to be absent. This suggests that increases in granular tau oligomer levels occur before NFTs form and before individuals manifest clinical symptoms of AD. Increased granular tau oligomer levels, therefore, may lead to NFT formation in frontal cortex, eventually leading to the development of AD. Thus, increases in granular tau oligomer levels may represent a very early sign of NFT formation and AD.
Similar articles
- Granular tau oligomers as intermediates of tau filaments.
Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A. Maeda S, et al. Biochemistry. 2007 Mar 27;46(12):3856-61. doi: 10.1021/bi061359o. Epub 2007 Mar 6. Biochemistry. 2007. PMID: 17338548 - [Drug development for tauopathy and Alzheimer's disease].
Takashima A. Takashima A. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010. PMID: 20857696 Review. Japanese. - [Significance of tau in the development of Alzheimer's disease].
Takashima A. Takashima A. Brain Nerve. 2010 Jul;62(7):701-8. Brain Nerve. 2010. PMID: 20675874 Review. Japanese. - Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.
Sahara N, Maeda S, Yoshiike Y, Mizoroki T, Yamashita S, Murayama M, Park JM, Saito Y, Murayama S, Takashima A. Sahara N, et al. J Neurosci Res. 2007 Nov 1;85(14):3098-108. doi: 10.1002/jnr.21417. J Neurosci Res. 2007. PMID: 17628496
Cited by
- The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease.
Blair LJ, Baker JD, Sabbagh JJ, Dickey CA. Blair LJ, et al. J Neurochem. 2015 Apr;133(1):1-13. doi: 10.1111/jnc.13033. Epub 2015 Feb 24. J Neurochem. 2015. PMID: 25628064 Free PMC article. Review. - Connectome-based biophysics models of Alzheimer's disease diagnosis and prognosis.
Torok J, Anand C, Verma P, Raj A. Torok J, et al. Transl Res. 2023 Apr;254:13-23. doi: 10.1016/j.trsl.2022.08.008. Epub 2022 Aug 27. Transl Res. 2023. PMID: 36031051 Free PMC article. Review. - Hippocampal gene expression meta-analysis identifies aging and age-associated spatial learning impairment (ASLI) genes and pathways.
Uddin RK, Singh SM. Uddin RK, et al. PLoS One. 2013 Jul 18;8(7):e69768. doi: 10.1371/journal.pone.0069768. Print 2013. PLoS One. 2013. PMID: 23874995 Free PMC article. - Tau Protein Squired by Molecular Chaperones During Alzheimer's Disease.
Gorantla NV, Chinnathambi S. Gorantla NV, et al. J Mol Neurosci. 2018 Nov;66(3):356-368. doi: 10.1007/s12031-018-1174-3. Epub 2018 Sep 28. J Mol Neurosci. 2018. PMID: 30267382 Review. - Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH, Lim CK, Ding Z, Wickramasinghe SP, Braun AR, Ashe KH, Rhoades E, Thomas DD, Sachs JN. Lo CH, et al. Alzheimers Dement. 2019 Nov;15(11):1489-1502. doi: 10.1016/j.jalz.2019.06.4954. Epub 2019 Oct 22. Alzheimers Dement. 2019. PMID: 31653529 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical